Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning / How Novo Nordisk Built a Moat on GLP-1 Patents and Scale
Transcript
- Lucas: If you look at the most valuable company in Europe by market cap right now, it's not a luxury conglomerate or an oil major — it's a Danish drugmaker that bet big on a gut hormone two decades ago. Luna: Novo Nordisk, with Ozempic and Wegovy. They've been on an absolute tear. Lucas: Exactly. And the question is: how durable is that lead? Because we're talking about a company whose market cap passed $500 billion this year, driven almost entirely by GLP-1 drugs. But the patent cliff is visible on the horizon, and every big pharma wants a piece of this market. Luna: So what's the actual moat? Is it the patents themselves, or something else? Lucas: It's a combination — what strategists call a 'moat stack.' First, there's intellectual property. Novo Nordisk has something like 100-plus patents protecting semaglutide, the active ingredient in Ozempic and Wegovy. Some cover the molecule itself, others cover formulations, dosing regimens, and manufacturing processes. That makes it really hard for a generic or biosimilar competitor to come in without getting sued. Luna: But patents expire. The basic composition patent on semaglutide expires in the US around 2032 in some territories. That's only six years away. Lucas: Right, but here's where the stack gets deeper. Novo has been aggressively building manufacturing scale. They spent over $6 billion on production capacity since 2020, including a $2.1 billion facility in France and expansions in Denmark and the US. GLP-1 drugs are peptides — they're chemically complex to synthesize. You can't just flip a switch and produce them. It takes years to build and validate a new plant. Luna: So even if a competitor gets FDA approval for a biosimilar, they can't make enough to supply the market. Lucas: Exactly. And Novo's not just making the drug — they're also making the delivery devices. The injection pens are proprietary, with their own patents. There's a whole ecosystem of manufacturing know-how that's incredibly hard to replicate. I read a Bernstein report that estimated it would take a competitor at least five years to build equivalent capacity, assuming they could even source the raw materials. Luna: And then there's the clinical data advantage. Novo has spent billions on trials showing cardiovascular benefits — Ozempic reduces heart attack risk, Wegovy showed a 20% reduction in cardiovascular death. That data is gold for doctors and insurers. Lucas: That's the third layer. The SELECT trial, which enrolled over 17,000 patients, showed Wegovy cut major cardiovascular events by 20%. That's a level of evidence no competitor has yet. And Novo now has over a decade of real-world data on millions of patients. For a hospital formulary committee or a pharmacy benefit manager, that track record is a powerful reason to stick with the incumbent. Luna: Let's talk about the competition. Eli Lilly has Mounjaro and Zepbound — tirzepatide — which some head to head data suggests is even more effective for weight loss. And Pfizer, Amgen, and others have oral GLP-1s in development. Lucas: Lilly is the biggest threat. They have a dual GIP and GLP-1 agonist, and they're investing heavily in capacity too — they announced a $4.5 billion manufacturing site in Indiana. But even Lilly, as big as they are, faces the same manufacturing bottlenecks. And Novo's lead in semaglutide isn't just about the molecule; it's about having the supply chain and the formulation expertise. For example, Novo developed a stable oral formulation of semaglutide — Rybelsus — which is one of the few oral peptides on the market. That's a huge formulation challenge. Luna: So the moat isn't just one thing — it's patents plus manufacturing plus clinical data plus formulation expertise. Lucas: Right. And there's a fifth element that often gets overlooked: the ownership structure. Novo Nordisk is controlled by the Novo Nordisk Foundation, which owns about 77% of the voting shares. That foundation is a nonprofit that reinvests profits into research and has a very long-term horizon. They're not worried about quarterly earnings pressure the way a typical public company is. That allowed them to spend $2 billion on R&D for GLP-1s long before the blockbuster revenue materialized. Luna: Patient capital. That's a real advantage in pharma, where the development cycle is often 15 years. Lucas: Exactly. Most companies would have killed the program after early failures. But Novo stuck with it because the foundation could afford to wait. Luna: Now, the worry for investors is that as patents expire, biosimilars will erode pricing. That happened with insulin — Novo's own insulin business saw pricing pressure from competitors like Sanofi and Lilly. Lucas: It's a valid concern. But GLP-1s are different from insulin in a few ways. First, the manufacturing complexity is higher, so biosimilar entry will be slower. Second, the market is growing incredibly fast — it's projected to be over $100 billion by 2030. Even if Novo loses some market share, the absolute revenue could still grow. And Novo is already working on next-generation drugs — like amycretin, an oral triple agonist — which could extend the moat. Luna: So the moat is real, but it's not permanent. The question is how well they use this window. Lucas: That's the strategic challenge. They need to use the current cash flow to build the next generation of drugs and further expand manufacturing. If they're complacent, the moat dries up. But given their track record and the foundation's long-term thinking, I'd bet they'll maintain a strong position. Luna: If today's deep dive on Novo's moat was useful to you, here's a thought: this show stays ad-free because of listener support. If you've gotten value from these episodes — maybe a new insight for your work — consider buying us a coffee at buy me a coffee dot com slash fexingo. It genuinely helps keep this going. Lucas: Yeah, and we mean it. Every contribution lets us spend more time on research and less on worrying about sponsors. So if you're in a position to chip in, we appreciate it. Luna: Alright, back to the moat. One more angle I want to explore: how Novo is using its position to expand into new indications. Lucas: Great point. They're running trials for semaglutide in fatty liver disease, Alzheimer's, and even addiction. If even one of those pans out, it extends the patent life and creates a new revenue stream. That's the ultimate moat — a platform that keeps generating new uses. Luna: So the takeaway: Novo's moat is a stack of patents, scale, data, and a patient owner. But the clock is ticking. Lucas: Exactly. Moats are never permanent — they're something you have to keep building. And Novo has a head start, but the race is on.